STOCK TITAN
  1. Home
  2. Sec-filings
  3. BBIO
  4. [Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

BridgeBio Strengthens Board Commitment with Major Director Stock Awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

BridgeBio Pharma Director Frank McCormick reported multiple equity transactions on June 20, 2025:

  • Received 6,589 Restricted Stock Units (RSUs) with $0 exercise price, vesting over 3 years through June 20, 2028
  • Granted 8,425 stock options with $41.73 exercise price, vesting over 3 years through June 20, 2028 and expiring June 19, 2035
  • Currently holds 979,979 shares indirectly through the Francis P. McCormick Rev Trust

Both RSUs and options are subject to continued service on BridgeBio's board of directors. The grants were made under the company's 2021 Amended and Restated Stock Option and Incentive Plan. Each RSU represents the right to receive one share of common stock upon vesting.

Positive

  • None.

Negative

  • None.
Insider MCCORMICK FRANK
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 8,425 $0.00 $0.00
Grant/Award Common Stock 6,589 $0.00 $0.00
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 8,425 shares (Direct); Common Stock — 83.275 shares (Direct); Common Stock — 979,979 shares (Indirect, By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017)
Footnotes (3)
  1. F1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.
  2. F2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
  3. F3. One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

How many BBIO shares were granted to Frank McCormick in June 2025?
Frank McCormick was granted 6,589 restricted stock units (RSUs) and 8,425 stock options of BBIO on June 20, 2025. The RSUs represent the right to receive an equal number of common stock shares.

What is the vesting schedule for BBIO's RSUs granted to Frank McCormick?
The RSUs will vest over a three-year period, with one-third vesting each year after June 20, 2025. Full vesting will occur on June 20, 2028, subject to McCormick's continued service on BBIO's board of directors.

What is the exercise price of BBIO stock options granted to Frank McCormick in June 2025?
The stock options were granted with an exercise price of $41.73 per share and will expire on June 19, 2035. These options were granted on June 20, 2025.

How many BBIO shares does Frank McCormick indirectly own through his trust?
Frank McCormick indirectly owns 979,979 shares of BBIO common stock through the Francis P. McCormick Rev Trust U/A DTD 1/27/2017.

What positions does Frank McCormick hold at BBIO according to the Form 4?
According to the Form 4 filing, Frank McCormick serves as a Director of BridgeBio Pharma, Inc. (BBIO). This is indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MCCORMICK FRANK
(Last) (First) (Middle)
C/O BRIDGEBIO PHARMA, INC.
3160 PORTER DR., SUITE 250
(Street)
PALO ALTO CA 94304
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 A(1) 6,589 A $0(2) 83.275 D
Common Stock 979,979 I By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $41.73 06/20/2025 A 8,425 (3) 06/19/2035 Common Stock 8,425 $0 8,425 D
Explanation of Responses:
1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.
2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
3. One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.
/s/ Frank McCormick, Ph.D., F.R.S., D.Sc. 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR